AC Immune S.A.(ACIU)Earnings, Financials & Key Ratios
ACIU•NASDAQ
Price updated Jun 19, 2026
AboutAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Show more
- Revenue$4M-86.9%
- EBITDA-$66M-32.1%
- Net Income-$70M-38.4%
- EPS (Diluted)-0.70-37.3%
- Gross Margin100%+177.4%
- EBITDA Margin-1857.26%-910.0%
- Operating Margin-1927.32%-904.9%
- Net Margin-1971.65%-957.5%
- ROE-89.62%-140.2%
ACIU Key Insights
AC Immune S.A. (ACIU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Sales declining 25.4% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ACIU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACIU Price & Volume
AC Immune S.A. (ACIU) stock price & volume — 10-year historical chart
Loading chart...
ACIU Growth Metrics
AC Immune S.A. (ACIU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-21.28%
5 Years-25.37%
3 Years-3.17%
TTM-86.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-38.15%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-37.25%
Return on Capital
10 Years-27.05%
5 Years-41.36%
3 Years-46.27%
Last Year-72.6%
ACIU Recent Earnings
AC Immune S.A. (ACIU) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (80%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.19+5.0%
$0.20
Rev
$1M+325.0%
$329,435
Q2 2026
Apr 29, 2026Metric
Actual
Est
EPS
$0.19+5.0%
$0.20
Rev
$1M+325.0%
$329,435
Q2 2026
Mar 13, 2026Metric
Actual
Est
EPS
$0.18+5.3%
$0.19
Rev
$428,876-70.3%
$1M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.20+9.1%
$0.22
Rev
$1M+3.2%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.19vs $0.20+5.0% | $1Mvs $329,435+325.0% |
| Q2 2026 | Apr 29, 2026 | $0.19vs $0.20+5.0% | $1Mvs $329,435+325.0% |
| Q2 2026 | Mar 13, 2026 | $0.18vs $0.19+5.3% | $428,876vs $1M-70.3% |
| Q4 2025 | Nov 4, 2025 | $0.20vs $0.22+9.1% | $1Mvs $1M+3.2% |
Based on last 12 quarters of dataView full earnings history →
ACIU Peer Comparison
AC Immune S.A. (ACIU) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 ANVS | 34.43M | 1.75 | -1.25 | -318.08% | ||||
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 |
Compare ACIU vs Peers
AC Immune S.A. (ACIU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACIU Income Statement
AC Immune S.A. (ACIU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 20.25M | 7.19M | 110.46M | 15.43M | 0 | 3.94M | 14.8M | 27.31M | 3.57M |
Revenue Growth % | -12.75% | -64.48% | 1435.39% | -86.03% | -100% | - | 276.14% | 84.51% | -86.92% |
Cost of Goods Sold | 32.66M | 44.28M | 50.43M | 59.49M | 0 | 0 | 54.61M | 62.57M | 0 |
COGS % of Revenue | 161.26% | 615.47% | 45.66% | 385.5% | - | - | 368.93% | 229.12% | - |
Gross Profit | -12.41M▲ 0% | -37.08M▼ 198.9% | 60.02M▲ 261.9% | -44.06M▼ 173.4% | 0▲ 100.0% | 3.94M▲ 0% | -39.8M▼ 1111.6% | -35.26M▲ 11.4% | 3.57M▲ 110.1% |
Gross Margin % | -61.26% | -515.47% | 54.34% | -285.5% | - | 100% | -268.93% | -129.12% | 100% |
Gross Profit Growth % | -384.69% | -198.86% | 261.86% | -173.4% | 100% | - | -1111.56% | 11.42% | 110.13% |
Operating Expenses | 42.79M | 56.74M | 15.49M | 17.2M | 79.01M | 74.78M | 13.82M | 17.12M | 72.44M |
OpEx % of Revenue | 211.28% | 788.77% | 14.02% | 111.49% | - | 1900.43% | 93.37% | 62.68% | 2027.32% |
Selling, General & Admin | 6.27M | 7.56M | 16.06M | 18.56M | 10.88M | 9.58M | 10.58M | 11.43M | 11.65M |
SG&A % of Revenue | 30.98% | 105.14% | 14.54% | 120.26% | - | 243.51% | 71.45% | 41.87% | 326.11% |
Research & Development | 32.66M | 44.28M | 50.43M | 59.49M | 62.28M | 60.34M | 54.61M | 62.57M | 56.44M |
R&D % of Revenue | 161.26% | 615.47% | 45.66% | 385.5% | - | 1533.32% | 368.93% | 229.12% | 1579.51% |
Other Operating Expenses | 3.86M | 4.9M | -51M | -60.84M | 5.85M | 4.86M | -51.36M | -56.89M | 4.35M |
Operating Income | -22.54M▲ 0% | -49.55M▼ 119.8% | 44.54M▲ 189.9% | -61.26M▼ 237.6% | -79.01M▼ 29.0% | -70.85M▲ 10.3% | -53.62M▲ 24.3% | -52.38M▲ 2.3% | -68.86M▼ 31.5% |
Operating Margin % | -111.28% | -688.77% | 40.32% | -396.99% | - | -1800.43% | -362.3% | -191.8% | -1927.32% |
Operating Income Growth % | -115.56% | -119.84% | 189.88% | -237.55% | -28.97% | 10.33% | 24.31% | 2.32% | -31.47% |
EBITDA | -21.96M | -48.59M | 45.81M | -59.73M | -76.6M | -68.49M | -51.41M | -50.22M | -66.36M |
EBITDA Margin % | -108.41% | -675.41% | 41.47% | -387.05% | - | -1740.48% | -347.33% | -183.88% | -1857.26% |
EBITDA Growth % | -115.75% | -121.27% | 194.28% | -230.38% | -28.26% | 10.59% | 24.94% | 2.32% | -32.15% |
D&A (Non-Cash Add-back) | 580K | 961K | 1.27M | 1.53M | 2.41M | 2.36M | 2.21M | 2.16M | 2.5M |
EBIT | -26.26M | -50.62M | 44.54M | -61.26M | -72.41M | -70.39M | -54.05M | -50.78M | -70.26M |
Net Interest Income | 176K | -207K | -1.62M | -106K | 5.9M | -286K | 868K | 3.06M | 1.67M |
Interest Income | 330K | 127K | 303K | 78K | 6.49M | 69K | 1.04M | 3.2M | 1.86M |
Interest Expense | 147K | 334K | 1.93M | 184K | 581K | 355K | 176K | 133K | 191K |
Other Income/Expense | -3.87M | -1.4M | 906K | -661K | 6.02M | 107K | -599K | 1.47M | -1.58M |
Pretax Income | -26.41M▲ 0% | -50.95M▼ 92.9% | 45.44M▲ 189.2% | -61.92M▼ 236.3% | -72.99M▼ 17.9% | -70.74M▲ 3.1% | -54.22M▲ 23.3% | -50.91M▲ 6.1% | -70.45M▼ 38.4% |
Pretax Margin % | -130.39% | -708.24% | 41.14% | -401.28% | - | -1797.71% | -366.35% | -186.43% | -1971.65% |
Income Tax | 147K | 0 | 0 | 0 | 3K | 13K | 10K | 3K | 0 |
Effective Tax Rate % | -0.56% | 0% | 0% | 0% | -0% | -0.02% | -0.02% | -0.01% | 0% |
Net Income | -26.41M▲ 0% | -50.95M▼ 92.9% | 45.44M▲ 189.2% | -61.92M▼ 236.3% | -73M▼ 17.9% | -70.75M▲ 3.1% | -54.23M▲ 23.3% | -50.92M▲ 6.1% | -70.45M▼ 38.4% |
Net Margin % | -130.39% | -708.24% | 41.14% | -401.28% | - | -1798.04% | -366.41% | -186.44% | -1971.65% |
Net Income Growth % | -272.2% | -92.92% | 189.19% | -236.26% | -17.89% | 3.07% | 23.35% | 6.12% | -38.36% |
Net Income (Continuing) | -26.41M | -50.95M | 45.44M | -61.92M | -73M | -70.75M | -54.23M | -50.92M | -70.45M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.46▲ 0% | -0.82▼ 78.3% | 0.64▲ 178.0% | -0.86▼ 234.4% | -0.97▼ 12.8% | -0.85▲ 12.4% | -0.64▲ 24.7% | -0.51▲ 20.3% | -0.70▼ 37.3% |
EPS Growth % | -228.57% | -78.26% | 178.05% | -234.38% | -12.79% | 12.37% | 24.71% | 20.31% | -37.25% |
EPS (Basic) | -0.46 | -0.82 | 0.64 | -0.86 | -0.97 | -0.85 | -0.64 | -0.51 | -0.70 |
Diluted Shares Outstanding | 57.36M | 61.84M | 71.1M | 71.9M | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
Basic Shares Outstanding | 57.08M | 61.84M | 70.6M | 71.9M | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ACIU Balance Sheet
AC Immune S.A. (ACIU) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 129.53M | 192.93M | 292.77M | 231.77M | 202.63M | 128.09M | 125.15M | 171.99M | 96.83M |
Cash & Short-Term Investments | 124.38M | 186.46M | 288.59M | 225.89M | 198.22M | 122.59M | 103.05M | 165.49M | 91.52M |
Cash Only | 124.38M | 156.46M | 193.59M | 160.89M | 82.22M | 31.59M | 78.49M | 36.27M | 26.83M |
Short-Term Investments | 0 | 30M | 95M | 65M | 116M | 91M | 24.55M | 129.21M | 64.69M |
Accounts Receivable | 3.72M | 4.1M | 1.4M | 1.59M | 975K | 408K | 15.05M | 1.1M | 681.77K |
Days Sales Outstanding | 66.98 | 208.12 | 4.62 | 37.63 | - | 37.84 | 371.04 | 14.69 | 69.65 |
Inventory | -1.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 329K | 428K | 392K | 622K | 1.1M | 0 |
Total Non-Current Assets | 2.48M | 3.63M | 6.48M | 6.97M | 58.81M | 57.84M | 57.66M | 58.92M | 57.59M |
Property, Plant & Equipment | 2.35M | 3.32M | 6.17M | 6.64M | 8.03M | 7.07M | 6.88M | 8.09M | 6.54M |
Fixed Asset Turnover | 8.61x | 2.16x | 17.90x | 2.32x | - | 0.56x | 2.15x | 3.38x | 0.55x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 50.42M | 50.42M | 50.42M | 50.42M | 50.47M |
Long-Term Investments | 126K | 304K | 304K | 0 | 0 | 0 | 361K | 0 | 584.66K |
Other Non-Current Assets | 0 | 0 | 0 | 334K | 363K | 361K | 0 | 415K | 0 |
Total Assets | 132.01M▲ 0% | 196.56M▲ 48.9% | 299.25M▲ 52.2% | 238.74M▼ 20.2% | 261.44M▲ 9.5% | 185.94M▼ 28.9% | 182.81M▼ 1.7% | 230.91M▲ 26.3% | 154.43M▼ 33.1% |
Asset Turnover | 0.15x | 0.04x | 0.37x | 0.06x | - | 0.02x | 0.08x | 0.12x | 0.02x |
Asset Growth % | -15.43% | 48.89% | 52.25% | -20.22% | 9.51% | -28.88% | -1.68% | 26.31% | -33.12% |
Total Current Liabilities | 9.75M | 13.08M | 17.51M | 14.02M | 20.03M | 11.48M | 13.58M | 100.84M | 94.8M |
Accounts Payable | 1.09M | 1.98M | 142K | 2.18M | 2M | 929K | 1.68M | 2.66M | 2.07M |
Days Payables Outstanding | 12.2 | 16.31 | 1.03 | 13.4 | - | - | 11.22 | 15.51 | - |
Short-Term Debt | 0 | 332K | 652K | 0 | 0 | 0 | 0 | 0 | 852.97K |
Deferred Revenue (Current) | 355K | 351K | 4.48M | 0 | 0 | 0 | 138K | 0 | 83.8M |
Other Current Liabilities | 0 | 0 | 0 | 306K | 717K | 587K | 0 | 85.06M | 3.83M |
Current Ratio | 13.28x | 14.75x | 16.72x | 16.53x | 10.12x | 11.16x | 9.22x | 1.71x | 1.02x |
Quick Ratio | 13.42x | 14.75x | 16.72x | 16.53x | 10.12x | 11.16x | 9.22x | 1.71x | 1.02x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 5.42M | 5.85M | 9.3M | 9.24M | 9.44M | 5.47M | 8.6M | 17.8M | 14.69M |
Long-Term Debt | 494K | 186K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 395K | 0 | 1.81M | 1.78M | 2.34M | 2.25M | 2.83M | 4.4M | 3.69M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4.53M | 5.67M | 7.49M | 7.46M | 7.1M | 3.21M | 5.77M | 13.4M | 8.66M |
Total Liabilities | 15.17M | 18.93M | 26.81M | 23.26M | 29.46M | 16.95M | 22.17M | 118.64M | 109.49M |
Total Debt | 395K | 518K | 2.91M | 2.22M | 2.91M | 2.8M | 3.5M | 5.43M | 4.55M |
Net Debt | -123.98M | -155.94M | -190.68M | -158.67M | -79.31M | -28.79M | -75M | -30.85M | -22.28M |
Debt / Equity | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.02x | 0.02x | 0.05x | 0.10x |
Debt / EBITDA | - | - | 0.06x | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | -4.16x | - | - | - | - | - | - |
Interest Coverage | -178.67x | -151.55x | 23.12x | -332.93x | -124.63x | -198.27x | -307.09x | -381.80x | -367.83x |
Total Equity | 116.84M▲ 0% | 177.62M▲ 52.0% | 272.44M▲ 53.4% | 215.48M▼ 20.9% | 231.98M▲ 7.7% | 168.99M▼ 27.2% | 160.64M▼ 4.9% | 112.27M▼ 30.1% | 44.93M▼ 60.0% |
Equity Growth % | -17.94% | 52.02% | 53.38% | -20.91% | 7.66% | -27.15% | -4.94% | -30.11% | -59.98% |
Book Value per Share | 2.04 | 2.87 | 3.83 | 3.00 | 3.10 | 2.02 | 1.90 | 1.13 | 0.45 |
Total Shareholders' Equity | 116.84M | 177.62M | 272.44M | 215.48M | 231.98M | 168.99M | 160.64M | 112.27M | 44.93M |
Common Stock | 1.15M | 1.35M | 1.44M | 1.54M | 1.79M | 1.8M | 2.09M | 2.23M | 2.26M |
Retained Earnings | -72.61M | -121.88M | -75.52M | -132.85M | -200.94M | -264.01M | -316.2M | -368.24M | -439.52M |
Treasury Stock | 0 | 0 | 0 | -100K | -124K | -124K | -105K | -218K | -218.25K |
Accumulated OCI | 179.35M | -3.54M | 0 | 0 | 0 | 10K | -51K | -5K | 7.01K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACIU Cash Flow Statement
AC Immune S.A. (ACIU) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -22.09M | -44.08M | 55.22M | -59.52M | -65.69M | -73.57M | -60.41M | 65.84M | -66.15M |
Operating CF Margin % | -109.08% | -612.7% | 49.99% | -385.7% | - | -1869.58% | -408.13% | 241.1% | -1851.33% |
Operating CF Growth % | -291.32% | -99.5% | 225.28% | -207.78% | -10.37% | -11.99% | 17.89% | 209% | -200.46% |
Net Income | -26.41M | -50.95M | 45.44M | -61.92M | -73M | -70.75M | -54.23M | -50.92M | -67.28M |
Depreciation & Amortization | 580K | 961K | 1.69M | 1.97M | 2.41M | 2.36M | 2.21M | 2.16M | 2.39M |
Stock-Based Compensation | 1.58M | 2.52M | 2.83M | 4.09M | 4.13M | 3.33M | 4.37M | 5.47M | 0 |
Deferred Taxes | 177K | 131K | 0 | 0 | 130K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.97M | 1.45M | -400K | 922K | -6.2M | -72K | 2.4M | 1.61M | 5.21M |
Working Capital Changes | -1.99M | 1.81M | 5.65M | -4.57M | 6.84M | -8.43M | -15.16M | 107.51M | -6.47M |
Change in Receivables | -401K | 698K | 2.5M | -532K | -99K | 603K | -14.8M | 13.55M | 877.68K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -2.85M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -565.38K |
Cash from Investing | -1.84M | -32.04M | -66.89M | 28.33M | -53.66M | 23.76M | 65.64M | -105.29M | 60.69M |
Capital Expenditures | -1.8M | -1.86M | -1.89M | -1.71M | -2.63M | -1.24M | -801K | -576K | -859.54K |
CapEx % of Revenue | 8.9% | 25.83% | 1.71% | 11.06% | - | 31.49% | 5.41% | 2.11% | 24.06% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.32K |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -40K | -178K | 0 | 30.04M | -51.03M | 25M | 66.45M | -104.71M | -162.36K |
Cash from Financing | 271K | 109.38M | 49.62M | -803K | 40.75M | -1.35M | 43.25M | -1.12M | -974.14K |
Debt Issued (Net) | 200K | 198K | 50.06M | -946K | 22.95M | -569K | -548K | -683K | -1.03M |
Equity Issued (Net) | 0 | 111.53M | 0 | 0 | 17.8M | -1K | 43.8M | 111K | 5.73K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -100K | 0 | -8K | 0 | 0 | 0 |
Other Financing | 71K | -2.35M | -441K | 143K | -6K | -776K | 0 | -548K | 46.13K |
Net Change in Cash | -27.83M▲ 0% | 32.09M▲ 215.3% | 37.13M▲ 15.7% | -32.69M▼ 188.1% | -78.68M▼ 140.6% | -50.63M▲ 35.6% | 46.91M▲ 192.6% | -42.22M▼ 190.0% | -4.92M▲ 88.3% |
Free Cash Flow | -23.9M▲ 0% | -45.94M▼ 92.2% | 53.34M▲ 216.1% | -61.22M▼ 214.8% | -68.32M▼ 11.6% | -74.81M▼ 9.5% | -61.21M▲ 18.2% | 65.27M▲ 206.6% | -67.01M▼ 202.7% |
FCF Margin % | -117.98% | -638.53% | 48.29% | -396.75% | - | -1901.07% | -413.55% | 238.99% | -1875.39% |
FCF Growth % | -265.1% | -92.23% | 216.11% | -214.79% | -11.6% | -9.49% | 18.18% | 206.63% | -202.67% |
FCF per Share | -0.42 | -0.74 | 0.75 | -0.85 | -0.91 | -0.90 | -0.72 | 0.65 | -0.67 |
FCF Conversion (FCF/Net Income) | 0.84x | 0.87x | 1.22x | 0.96x | 0.90x | 1.04x | 1.11x | -1.29x | 0.94x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACIU Key Ratios
AC Immune S.A. (ACIU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -6.65% | -20.38% | -34.61% | 20.19% | -25.38% | -32.63% | -35.29% | -32.91% | -37.31% | -89.62% |
Return on Invested Capital (ROIC) | - | - | -511.32% | 64.58% | -66.31% | -56.58% | -36.28% | -35.61% | -47.03% | -99.25% |
Gross Margin | -11.03% | -61.26% | -515.47% | 54.34% | -285.5% | - | 100% | -268.93% | -129.12% | 100% |
Net Margin | -30.57% | -130.39% | -708.24% | 41.14% | -401.28% | - | -1798.04% | -366.41% | -186.44% | -1971.65% |
Debt / Equity | - | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.02x | 0.02x | 0.05x | 0.10x |
Interest Coverage | -27.69x | -178.67x | -151.55x | 23.12x | -332.93x | -124.63x | -198.27x | -307.09x | -381.80x | -367.83x |
FCF Conversion | 0.80x | 0.84x | 0.87x | 1.22x | 0.96x | 0.90x | 1.04x | 1.11x | -1.29x | 0.94x |
Revenue Growth | -40.61% | -12.75% | -64.48% | 1435.39% | -86.03% | -100% | - | 276.14% | 84.51% | -86.92% |
Related:ACIU Dividend History·ACIU Revenue History·ACIU Price History·ACIU P/E History·ACIU Financial Ratios·ACIU Institutional Holders
ACIU Frequently Asked Questions
AC Immune S.A. (ACIU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AC Immune S.A. (ACIU) reported $3.6M in revenue for fiscal year 2025. This represents a 59% decrease from $8.6M in 2013.
AC Immune S.A. (ACIU) saw revenue decline by 86.9% over the past year.
AC Immune S.A. (ACIU) reported a net loss of $70.3M for fiscal year 2025.
Dividend & Returns
AC Immune S.A. (ACIU) has a return on equity (ROE) of -89.6%. Negative ROE indicates the company is unprofitable.
AC Immune S.A. (ACIU) had negative free cash flow of $70.1M in fiscal year 2025, likely due to heavy capital investments.